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Abstract
Background: EPHX1 is a key enzyme in metabolizing some exogenous carcinogens such as products of cigarette-smoking.
Two functional polymorphisms in the EPHX1 gene, Tyr113His and His139Arg can alter the enzyme activity, suggesting their
possible association with carcinogenesis risk, particularly of some tobacco-related cancers.
Methodology/Principal Findings: A comprehensive systematic review and meta-analysis was performed of available
studies on these two polymorphisms and cancer risk published up to November 2010, consisting of 84 studies (31144 cases
and 42439 controls) for Tyr113His and 77 studies (28496 cases and 38506 controls) for His139Arg primarily focused on lung
cancer, upper aerodigestive tract (UADT) cancers (including oral, pharynx, larynx and esophagus cancers), colorectal cancer
or adenoma, bladder cancer and breast cancer. Results showed that Y113H low activity allele (H) was significantly associated
with decreased risk of lung cancer (OR=0.88, 95%CI=0.80–0.96) and UADT cancers (OR=0.86, 95%CI=0.77–0.97) and
H139R high activity allele (R) with increased risk of lung cancer (OR=1.18, 95%CI=1.04–1.33) but not of UADT cancers
(OR=1.05, 95%CI=0.93–1.17). Pooled analysis of lung and UADT cancers revealed that low EPHX1 enzyme activity,
predicted by the combination of Y113H and H139R showed decreased risk of these cancers (OR=0.83, 95%CI=0.75–0.93)
whereas high EPHX1 activity increased risk of the cancers (OR=1.20, 95%CI=0.98–1.46). Furthermore, modest difference for
the risk of lung and UADT cancers was found between cigarette smokers and nonsmokers both in single SNP analyses (low
activity allele H: OR=0.77/0.85 for smokers/nonsmokers; high activity allele R: OR=1.20/1.09 for smokers/nonsmokers) and
in combined double SNP analyses (putative low activity: OR=0.73/0.88 for smokers/nonsmokers; putative high activity:
OR=1.02/0.93 for smokers/ nonsmokers).
Conclusions/Significance: Putative low EPHX1 enzyme activity may have a potential protective effect on tobacco-related
carcinogenesis of lung and UADT cancers, whereas putative high EPHX1 activity may have a harmful effect. Moreover,
cigarette-smoking status may influence the association of EPHX1 enzyme activity and the related cancer risk.
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Introduction
Human microsomal epoxide hydrolase (EPHX1 or mEH, EC
3.3.2.9) plays an important role during xenobiotic detoxification of
exogenous chemicals such as polycyclic aromatic hydrocarbons
(PAHs) which are produced during the use of coal tar, coke,
bitumen, or during cigarette smoking [1–3]. On the other hand, it
is also involved in the xenobiotic activation of some carcinogens
[4–6]. EPHX1 also hydrolyzes arene, alkene, and aliphatic
epoxides, which are metabolic products from PAHs and aromatic
amines by cytochrome P450 and other phase I enzymes catalysis
[1].
The human EPHX1 gene is 35.48 kb with nine exons and eight
introns on chromosome 1q42.1. To date, more than 110 single
nucleotide polymorphisms (SNPs) have been identified according
to the NCBI’s dbSNP database. Two SNPs among them,
Tyr113His (rs1051740, in exon 3) and His139Arg (rs2234922, in
exon 4), have been well characterized both in vitro studies and
epidemiological investigation. Early in vitro studies showed that
EPHX1 enzymatic activity was decreased by approximately 40%
in subjects with the His113 allele (low EPHX1 activity allele) and
increased by at least 25% with the Arg139 allele (high EPHX1
activity allele) [7,8]. Given the known differential effect of EPHX1
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that these polymorphisms may affect cancer risk. Later population
studies found that these two functional polymorphisms were
strongly associated with susceptibility to a number of cancers, such
as lung cancer [9–12], upper aerodigestive tract (UADT) cancers
[13,14], colorectal cancer or adenoma [15,16], bladder cancer
[17], breast cancer [18]. Based on the genotype combination of
these two functional polymorphisms, Benhamou and colleagues
[9] classified EPHX1 activity as putative low activity (113HH/
139HH, 113HH/139HR and 113YH/139HH), intermediate
activity (113HH/139RR, 113YY/139HH and 113YH/139HR)
and high activity (113YH/139RR, 113YY/139HR and 113YY/
139RR). They also found a significant association with lung cancer
risk between cases exhibiting putative high and intermediate
EPHX1 activity compared to low activity cases in Caucasian
cigarette smokers [9]. A previous meta-analysis of the association
of these SNPs with lung cancer revealed that the low-activity
genotype (HH) of EPHX1 polymorphism Y113H was associated
with decreased risk of lung cancer while the high-activity genotype
(RR) of polymorphism H139R was associated with a modest
increase risk of lung cancer among Caucasians. Moreover, the
predicted low activity by genotype combination of two polymor-
phisms was associated with a modest decrease of lung cancer risk
[19]. However, it has not been well clarified whether EPHX1
enzymatic activity is associated with cancer risk.
The present comprehensive meta-analysis of published epide-
miological studies aims to systematically evaluate putative EPHX1
enzyme activity and risk of cancers predicted by single
polymorphism of Y113H/H139R and by combined double
polymorphisms, and to identify the association between these
two functional polymorphisms and risk of some tobacco-related
cancers.
Materials and Methods
Search strategy
All case-control studies of EPHX1 polymorphisms and cancer
risk published up to November 1, 2010 were identified through
comprehensive searches in PubMed, EMBASE, ISI Web of
Science and Google Scholar. The search terms used were: EPHX1,
microsomal epoxide hydrolase and mEH in combination with polymor-
phism, variation, genotype, genetic and mutation, and in combination with
cancer, tumor, tumour, carcinoma, adenoma and adenocarcinoma. For each
identified study, additional studies were sought from its references,
citations and from the PubMed option ‘Related Articles’.
Selection
The following criteria were employed to determine inclusion of
a study in this meta-analysis: 1) a case–control study evaluating at
least one of these two polymorphisms (Y113H and H139R) and
cancer risk; 2) no overlapping data. All data were independent of
each other. For the same or overlapping data in the studies
published by the same researchers, we selected the most recent
study with a larger number of participants; 3) full-text articles; 4)
published in English language journals.
Data Extraction
The collected data items included: first author, published year,
cancer type, study design, original country, sample ethnicity,
sample size, genotype counts and genotyping method. The data
Figure 1. Flow chart of study selection.
doi:10.1371/journal.pone.0014749.g001
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Y113H H139R
Cancer group Low vs. Random effects P-value P-value for I2 High vs.
Random
effects P-value P-value for I2
(Studies and
cases/controls) Intermediate OR (95% CI) heterogeneity Intermediate OR (95% CI) heterogeneity
Overall (N=84; 31144/
42439)
(N=77; 28496/
38506)
H vs. Y 0.99 (0.95–1.03) 0.574 ,0.001 61.4% R vs. H 1.02 (0.98–1.06) 0.470 0.002 35.5%
YH vs. YY 0.94 (0.90–0.99) 0.016 ,0.001 43.2% HR vs. HH 1.00 (0.95–1.04) 0.868 0.011 29.1%
HH vs. YY 1.02 (0.94–1.12) 0.592 ,0.001 59.2% RR vs. HH 1.08 (0.98–1.20) 0.141 0.043 23.0%
Lung cancer (N=18; 4819/
9049)
(N=18; 6742/
9151)
H vs. Y 0.88 (0.80–0.96) 0.005 0.033 41.7% R vs. H 1.18 (1.04–1.33) 0.010 , 0.001 68.3%
YH vs. YY 0.86 (0.78–0.95) 0.003 0.272 15.2% HR vs. HH 1.19 (1.04–1.36) 0.012 0.001 59.4%
HH vs. YY 0.81 (0.65–1.00) 0.048 0.037 41.9% RR vs. HH 1.22 (0.92–1.63) 0.162 0.018 45.7%
UADT cancers (N=15; 3285/
5324)
(N=14; 2963/
4867)
H vs. Y 0.86 (0.77–0.97) 0.014 0.002 58.8% R vs. H 1.05 (0.93–1.17) 0.447 0.110 33.1%
YH vs. YY 0.77 (0.66–0.90) 0.001 0.027 45.9% HR vs. HH 1.00 (0.87–1.17) 0.874 0.138 29.9%
HH vs. YY 0.82 (0.66–1.03) 0.084 0.010 51.8% RR vs. HH 1.34 (0.98–1.82) 0.065 0.252 18.5%
Colorectal
cancer
(N=11; 5283/
6903)
(N=10; 4456/
5669)
H vs. Y 1.04 (0.96–1.13) 0.310 0.089 40.3% R vs. H 0.95 (0.88–1.02) 0.144 0.857 0.0%
YH vs. YY 1.05 (0.97–1.14) 0.199 0.820 0.0% HR vs. HH 0.91 (0.84–1.00) 0.041 0.806 0.0%
HH vs. YY 1.11 (0.89–1.39) 0.351 0.005 61.8% RR vs. HH 1.01 (0.82–1.26) 0.897 0.545 0.0%
Colorectal
adenoma
(N=8; 4012/
4057)
(N=9; 4857/
4929)
H vs. Y 0.95 (0.88–1.03) 0.224 0.259 21.4% R vs. H 1.05 (0.98–1.13) 0.193 0.490 0.0%
YH vs. YY 0.94 (0.86–1.04) 0.239 0.510 0.0% HR vs. HH 1.04 (0.95–1.13) 0.418 0.696 0.0%
HH vs. YY 0.92 (0.78–1.09) 0.319 0.212 27.1% RR vs. HH 1.13 (0.92–1.38) 0.233 0.460 0.0%
Breast cancer (N=6; 6090/
7797)
(N=4; 4543/
6899)
H vs. Y 0.98 (0.90–1.07) 0.696 0.123 42.3% R vs. H 0.96 (0.89–1.02) 0.200 0.835 0.0%
YH vs. YY 0.97 (0.90–1.04) 0.411 0.618 0.0% HR vs. HH 0.95 (0.87–1.03) 0.202 0.749 0.0%
HH vs. YY 1.06 (0.81–1.39) 0.680 0.002 72.8% RR vs. HH 0.94 (0.78–1.15) 0.557 0.634 0.0%
Bladder cancer (N=5; 1810/
1869)
(N=4; 1614/
1656)
H vs. Y 1.17 (0.92–1.49) 0.192 0.002 76.6% R vs. H 0.89 (0.76–1.05) 0.168 0.262 25.0%
YH vs. YY 1.25 (0.90–1.75) 0.183 0.006 72.1% HR vs. HH 0.91 (0.78–1.06) 0.240 0.610 0.0%
HH vs. YY 1.27 (0.84–1.92) 0.266 0.015 67.4% RR vs. HH 0.73 (0.40–1.32) 0.300 0.155 42.8%
Blood cancers (N=7; 1844/
2028)
(N=10; 2217/
3067)
H vs. Y 0.98 (0.86–1.11) 0.743 0.255 22.8% R vs. H 0.95 (0.86–1.05) 0.318 0.426 1.3%
YH vs. YY 0.78 (0.60–1.00) 0.046 0.059 50.6% HR vs. HH 0.96 (0.82–1.12) 0.607 0.241 22.0%
HH vs. YY 1.08 (0.85–1.37) 0.513 0.329 13.2% RR vs. HH 0.96 (0.62–1.48) 0.838 0.136 35.2%
Liver cancer (N=4; 368/
859)
(N=3; 212/
556)
H vs. Y 1.05 (0.74–1.48) 0.790 0.036 65.0% R vs. H 1.11 (0.80–1.54) 0.537 0.222 33.6%
YH vs. YY 0.90 (0.59–1.39) 0.639 0.087 54.4% HR vs. HH 1.18 (0.83–1.68) 0.366 0.738 0.0%
HH vs. YY 1.16 (0.57–2.40) 0.681 0.049 61.8% RR vs. HH 1.05 (0.34–3.29) 0.927 0.116 53.6%
UADT, upper aerodigestive tract; N, number of studies.
doi:10.1371/journal.pone.0014749.t001
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and rechecked by Hu. All item-specific ambiguities were clarified
by investigators’ consultation. Different case-control groups in
one study were considered as independent studies. Cigarette
smoking status was strategically classified as current smokers and
nonsmokers.
Quantitative data synthesis
To evaluate the association of EPHX1 polymorphisms with
carcinogenesis risk, we treated wild-type Y of Y113H and H of
H139R as intermediate activity alleles and treated wild-type YY of
Y113H and HH of H139R as intermediate activity genotypes.
They are the comparison references for calculating odds ratios.
Thus comparisons are Low activity vs. Intermediate activity (H vs.
Y, YH vs. YY and HH vs. YY) and High activity vs. Intermediate
activity (R vs. H, HR vs. HH and RR vs. HH) (Table S1).
EPHX1 enzymatic activity was also predicted by double
polymorphisms based on the method of Benhamou 1998 [9]
namely low activity (113HH/139HH, 113HH/139HR and
113YH/139HH), intermediate activity (113HH/139RR, 113YY/
139HH and 113YH/139HR) and high activity (113YH/139RR,
113YY/139HR and 113YY/139RR) (Table S1).
Random-effects methods [20] were used to calculate pooled odds
ratios (ORs) and the associated 95% confidence intervals (CIs).
The Cochran’s Q statistic [21] and the inconsistency index I
2
[22] were used to evaluate the between-study heterogeneity.
Random effect meta-regression models with restricted maximum
likelihood estimation were employed to evaluate the different
variance among the individual ORs when heterogeneity was
detected. The pre-specified possible sources of inter-study
heterogeneity were: cancer type, ethnicity of population (Cauca-
sian, East Asian, South Asian, African or Mixed population), study
design (hospital-based case-control study, population-based case-
control study or nested case-control study), sample size ($500 or
,500) and HWE violation (violated or not violated). Furthermore,
the sensitive analysis method proposed by Patsopoulos et al. was
implemented to identify studies which may be the main source of
the measured heterogeneity [23].
To detect potential publication bias, funnel plots [24] were
applied by plotting individual study log OR against the standard
error of the log OR. Plots should resemble a symmetrical inverted
funnel if ascertainment bias was absent. Publication bias was also
assessed using Egger’s test [25], by which asymmetry in a funnel
plot could be tested.
Except for heterogeneity statistics (where significance was
declared if P-value , 0.10), all results were considered
‘‘significant’’ if the corresponding P-value was , 0.05. All P-
values were 2-sided. The statistical analyses were performed using
STATA 11.0 (STATA Corp, College Station, Texas).
Results
Flow of included studies
Initially a total of 315 potentially relevant publications up to
November 1, 2010 were identified through PubMed, EMBASE,
ISI Web of Science and Google Scholar. 227 studies were
excluded because of insufficient information related to pre-
specified inclusion criteria. Further six studies were excluded
because of a duplicated publication or for not providing complete
genotypes data [26–31]. The reasons for exclusion of each case-
control study were detailed in Text S1. Finally, 82 articles [9–
18,32–103] were selected in the meta-analysis, of which 9 articles
[14,34,37,42,61,64,71,84,88] had two independent studies and
were considered separately. Therefore, a total of 91 studies, of
which 84 studies (31144 cases and 42439 controls) for Tyr113His
and 77 studies (28496 cases and 38506 controls) for His139Arg
Table 2. Summary ORs for association of EPHX1 polymorphisms Y113H and H139R with pooled lung and upper aerodigestive tract
(UADT) cancers.
Y113H H139R
Study group N
Random effects OR
(95% CI) P-value
P-value
for I2 N
Random effects OR
(95% CI) P-value P-value for I2
Low vs. Intermediate
(H vs. Y)
heterog-
eneity
High vs. Intermediate
(R vs. H) heterogeneity
Overall
Lung + UADT 33 0.87 (0.81–0.94) 0.0002 0.001 49.3% 32 1.12 (1.03–1.22) 0.011 ,0.001 58.0%
Ethnicity
Caucasian 21 0.87 (0.81–0.94) 0.0005 0.015 44.5% 24 1.07 (0.97–1.15) 0.228 0.001 58.7%
Asian 6 1.02 (0.89–1.16) 0.806 0.553 0.0% 3 1.52 (1.13–2.05) 0.006 0.438 0.0%
African 3 0.83 (0.63–1.09) 0.175 0.619 0.0% 3 1.26 (1.01–1.57) 0.040 0.741 0.0%
Study design
Population-based 21 0.88 (0.80–0.96) 0.006 0.026 41.3% 18 1.15 (1.01–1.31) 0.033 ,0.001 64.2%
Hospital-based 9 0.82 (0.68–0.98) 0.031 0.004 64.3% 10 1.09 (0.96–1.25) 0.187 0.310 14.5%
Sample size
$500 10 0.91 (0.84–0.98) 0.022 0.061 44.7% 10 1.02 (0.92–1.13) 0.695 0.001 67.6%
,500 23 0.85 (0.76–0.95) 0.004 0.005 48.5% 22 1.21 (1.07–1.37) 0.002 0.038 38.0%
Smoke status *
Nonsmokers 7 0.85 (0.69–1.06) 0.152 0.942 0.0% 4 1.09 (0.70–1.68) 0.709 0.130 46.9%
Smokers 7 0.77 (0.65–0.91) 0.002 0.664 0.0% 7 1.20 (0.93–1.55) 0.152 0.119 40.8%
N, number of studies; * YH+HH vs. YY for Y113H; HR+RR vs. HH for H139R.
doi:10.1371/journal.pone.0014749.t002
EPHX1 and Cancer Risk
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e14749dominated by lung cancer, UADT, colorectal cancer, colorectal
adenoma, bladder cancer, breast cancer, liver cancer and blood
cancers (leukemia, lymphoma and multiple myeloma) were
included in the meta-analysis based on our search strategy and
eligibility criteria (Table S2 and Figure 1).
Study characteristics
Detailed characteristics of the aggregated data for 91 case-
control studies are listed in Table S2. Minor allele frequency of
Y113H and H139R of controls in different populations graphed as
Figure S1. Among overall studies, 24 studies (6418 cases and 9516
controls) that further evaluated the putative EPHX1 enzyme
activity and cancer risk by the method described by Benhamou
et al. [9] are characterized in Table S3.
Quantitative data synthesis
EPHX1 polymorphisms Y113H and H139R and cancer
risk. The associations of each of EPHX1 Y113H and H139R
Figure 2. Forest plots describing the association of EPHX1 polymorphism Y113H with lung and upper aerodigestive tract (UADT)
cancers. ORs were calculated by comparing the low activity allele H vs. the intermediate activity allele Y in lung and UADT cancers. P-values of the
ORs are calculated with the DerSimonian-Laird method using a random effects model and measurements of heterogeneity are based on Cochran’s Q-
test and the inconsistency index I
2.
doi:10.1371/journal.pone.0014749.g002
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cancer risk of EPHX1 Y113H and H139R polymorphisms in
different cancer types were shown in Table 1. The overall OR by
the random-effects model showed no significant association
between Y113H or H139R and cancer risk except between the
heterozygote versus wild-type Y113H allele (YH vs. YY), which
exhibited a slightly decreased cancer risk (OR=0.94,
95%CI=0.90–0.99; P=0.016). Results of analyzing these two
polymorphisms in different cancer types revealed that the low
activity allele (H) of Y113H was highly associated with decreased
risk of lung cancer (OR=0.88, 95%CI=0.80–0.96; P=0.005)
and UADT (OR=0.86, 95%CI=0.77–0.97; P=0.014); the high
activity allele (R) of H139R was significantly associated with
increased risk of lung cancer (OR=1.18, 95%CI=1.04–1.33;
P=0.010) but not of UADT (OR=1.05, 95%CI=0.93–1.17,
P=0.447). However, the homozygous variant (RR) of H139R
showed increased risk of UADT cancers (OR=1.34,
95%CI=0.98–1.82, P=0.065). Towards other assessed cancers,
i.e., colorectal cancer, colorectal adenoma, breast cancer, bladder
cancer, blood cancers (leukemia, lymphoma and multiple
myeloma) or liver cancer, the study revealed only modest
decreased or increased effects on cancer risk: Y113H for blood
cancers (YH vs. YY: OR=0.78, 95%CI=0.60–1.00) and H139R
for colorectal cancer (HR vs. HH: OR=0.91, 95%CI=0.84–
1.00). No statistically significant association was observed for each
polymorphism with other cancer cases. Interestingly, though not
significant, the low activity of Y113H showed increased risk of
bladder cancer (H vs. Y: OR=1.17, 95%CI=0.92–1.49; HH vs.
YY: OR=1.27, 95%CI=0.84–1.92) whereas high activity of
H139R showed decreased risk of bladder cancer (R vs. H:
OR=0.89, 95%CI=0.76–1.05; RR vs. HH: OR=0.73,
95%CI=0.84–1.92) (Table 1).
As lung and UADT cancers share a similar etiology and
association with tobacco usage [104], we pooled lung and UADT
cancers together to further explore the cancer risk of polymor-
phisms Y113H and H139R. We found that the low activity allele
(H) of Y113H presented a significant association with decreased
cancer risk (OR=0.87, 95%CI=0.81–0.94; P=0.0002) (Table 2
and Figure 2), whereas the high activity allele (R) of H139R
presented a modest association with increased cancer risk
(OR=1.12, 95%CI=1.03–1.22; P=0.011) (Table 2).
The ethnicity, study design, sample size and smoke status of
pooled lung and UADT cancer risk carrying the low enzymatic
activity allele (H) of Y113H or the high enzymatic activity allele
(R) of H139R was calculated and a modest difference between
cigarette smokers and nonsmokers was observed (Table 2). The
odds ratio for the low activity allele (H) of polymorphism Y113H
in smokers was 0.77 (95%CI=0.65–0.91, P=0.002) and 0.85
(95%CI=0.69–1.06, P=0.152) in nonsmokers. The odds ratio for
high activity allele (R) of polymorphism H139R was 1.20
(95%CI=0.93–1.55, P=0.152) in smokers and 1.09
(95%CI=0.70–1.68, P=0.709) in nonsmokers.
Putative EPHX1 enzyme activity and risk of lung and
UADT cancers. In order to evaluate the association of these two
functional polymorphisms and their enzyme activity with
carcinogenesis risk, we analyzed the association of EPHX1
enzyme activity predicted by genotype combination of
polymorphism Y113H and H139R with risk of lung and UADT
cancers. In an overall comparison to the putative intermediate
EPHX1 activity, low EPHX1 activity decreased risk of lung and
UADT cancers significantly (OR=0.83; 95%CI=0.75–0.93,
P=0.001) and high EPHX1 activity increased the cancer risk
(OR=1.20; 95%CI=0.98–1.46; P=0.081) (Table 3 and Figure 3).
The association of EPHX1 enzyme activity predicted by the
combination of these two polymorphisms with the risk of cigarette
smoker or nonsmoker in pooled lung and UADT cancers was
further assessed. Similar results with the single SNP analysis were
obtained: modest, non-significant differences of ORs of putative
EPHX1 enzyme activity between cigarette smokers and nonsmok-
ers. The odds ratio of putative low enzyme activity was 0.73
(95%CI=0.58–0.93; P=0.009) in smokers and 0.88
(95%CI=0.61–1.28) in nonsmokers while the odds ratio of
Table 3. Summary ORs for association of putative EPHX1 enzyme activity by Y113H/H139R genotype combination with lung and
upper aerodigestive tract (UADT) cancers.
Low vs. Intermediate High vs. Intermediate
Study group N (cases/controls) Random effects P value P-value for I2 Random effects P value P-value for I2
OR (95%CI)
heterog-
eneity OR (95%CI)
heterog-
eneity
Overall
Lung + UADT 17 (2928/5436) 0.83 (0.75–0.93) 0.001 0.584 0.0% 1.20 (0.98–1.46) 0.081 0.005 53.5%
Ethnicity
Caucasian 15 (2692/5072) 0.83 (0.74–0.94) 0.002 0.483 0.0% 1.20 (0.95–1.51) 0.125 0.002 58.9%
African 2 (236/364) 0.85 (0.54–1.35) 0.497 0.427 0.0% 1.22 (0.86–1.76) 0.287 0.625 0.0%
Study design
Hospital-based 6 (959/1063) 0.75 (0.59–0.95) 0.016 0.273 21.3% 1.30 (0.96–1.76) 0.087 0.177 34.6%
Population-based 11 (1969/4373) 0.88 (0.77–1.00) 0.050 0.799 0.0% 1.15 (0.88–1.50) 0.303 0.004 60.9%
Sample size
$500 5 (1296/3606) 0.83 (0.71–0.97) 0.020 0.633 0.0% 0.85 (0.63–1.13) 0.263 0.074 53.1%
,500 12(1632/1830) 0.84 (0.70–0.99) 0.036 0.393 5.3% 1.44 (1.20–1.73) 0.0001 0.411 3.5%
Smoke status
Nonsmokers 2 (191/1719) 0.88 (0.61–1.28) 0.517 0.535 0.0% 0.93 (0.58–1.51) 0.777 0.866 0.0%
Smokers 4 (620/1132) 0.73 (0.58–0.93) 0.009 0.825 0.0% 1.02 (0.68–1.53) 0.928 0.136 46.0%
doi:10.1371/journal.pone.0014749.t003
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e14749putative high enzyme activity was 1.02 (95%CI=0.68–1.53) in
smokers and the 0.93 (95%CI=0.58–1.51) in nonsmokers
(Table 3).
Between-study heterogeneity. Obvious Between-study
heterogeneity was detected among pooled lung and UADT
cancer studies on I
2 measures of 49.3% (P=0.001) and 58.0%
(P,0.001) for H vs. Y of Y113H and R vs. H of H139R,
respectively. After subgroup analysis by ethnicity, we found
heterogeneity was only obvious in Caucasian (H vs. Y of
Y113H: I
2=44.5%, P=0.015; R vs. H of H139R: I
2=58.7%,
P=0.001) but not in Asian and African descents (Table 2).
By further univariate meta-regression analysis, we identified that
it is population ethnicity (b coefficient=0.12 (0.03–0.21),
P=0.021) that was a significant source of heterogeneity for R vs.
H of H139R but not cancer type, study design, sample size,
genotyping method or HWE-violation (Table S4). Actually, it has
shown that the high activity allele (R) of H139R significantly
increased the cancer risk in Asians (OR=1.52, 95%CI=1.13–
2.05) and Africans (OR=1.26, 95%CI=1.01–1.57) but not in
Caucasians (OR=1.07, 95%CI=0.97–1.15) in pooled analysis.
These results emphasized that the population heterogeneity of
polymorphism H139R was associated with cancer risk. None of
cancer type, ethnicity, study design, sample size, genotyping
method or HWE-violation was found to be the source of
heterogeneity for H vs. Y of Y113H (Table S4).
In the analysis of putative EPHX1 enzyme activity and risk of
lung and UADT cancers, obvious between-study heterogeneity
was identified for high vs. intermediate (I
2=53.5%, P=0.005)
(Table 3). Sample size was found the main source of heterogeneity
(b coefficient=0.53 (0.19–0.88), P=0.005). When the studied
samples were classified into large size subgroup ($500, OR=0.85,
95%CI=0.63–1.13) and small size one (,500, OR=1.44,
95%CI=1.20–1.73), unexpectedly, it brought about the results
that heterogeneity was still obvious in large sample subgroup
(I
2=53.1%, P=0.074) but not in small sample subgroup
(I
2=3.5%, P=0.411) (Table 3).
Sensitive analysis. Applying sensitive analysis method of
Patsopoulos et al [23], we found studies of Jourenkova-Mironova
[13], Benhamou [9] and Voho [41] contributed mostly to the
heterogeneity in comparison of H vs. Y of Y113H in Caucasians.
After excluded these three studies, the index I
2 decreased
significantly from 44.5% (P=0.015) to 18.5% (P=0.232) and
odds ratio became 0.92 (95%CI=0.87–0.98). In comparison of R
vs. H of H139R, studies of Zienolddiny [12] and Graziano [44]
contributed the most to heterogeneity in Caucasians. After
excluded them, the index I
2 decreased from 58.7% (P=0.001) to
20.0% (P=0.202) and odds ratio became 1.00 (95%CI=0.94–
1.06). These results indicated that the high activity allele (R) of
H139R may be not associated with lung and UADT cancer risk in
Caucasians when considering omitting heterogeneity-caused
studies.
Three studies of Cajas-Salazar [40], Voho [41] and London a
[34] were identified to contribute to the heterogeneity for high vs.
intermediate of putative EPHX1 enzyme activity. After excluded
them, the index I
2 decreased from 53.5% (P=0.005) to 0.0%
(P=0.42) and odds ratio became 1.23 (95%=1.06–1.42).
Interestingly, the both studies of Cajas-Salazar [40] and Voho
[41] were belong to the large sample subgroup ($500). Therefore,
though in large sample subgroup putative high activity showed
decreased risk of lung and UADT caners, the studies were quite
heterogeneous and the authentic role of EPHX1 high activity
might increase risk of lung and UADT caners as data showed
above.
Publication bias. By Begg’s funnel plot and Egger’s test, the
results revealed a significant publication bias for H vs. Y of Y113H
(P=0.003) in the pooled analysis of lung and UADT cancers but
not for R vs. H of H139R (P=0.141) (Figure S2). Among all
studies, four studies of Zienolddiny [12], Ihsan [56], Graziano [44]
and Wu a [37] were detected to deviate remarkably from other
symmetrically distributed studies in the funnel plot (Figure S2).
These four studies were exactly the source of heterogeneity from
Patsopoulos et al’s sensitive analysis in pooled dataset of lung and
UADT cancers. When omitted these four studies, Egger’s test P-
value turned into 0.124, and I
2 decreased from 57.6% (P for
heterogeneity ,0.001) to 12.6% (P for heterogeneity ,0.276).
Discussion
The present meta-analysis provides the most comprehensive
and up-to-date evidence on putative EPHX1 enzyme activity
predicted from two genetic polymorphisms, Y113H and H139R,
and risk of developing cancers. Though a number of early studies
showed the two polymorphisms functionally affect the EPHX1
enzymatic activity [7,8] and are associated with certain cancers
[9–18], our systematic analyses revealed that both Y113H low
enzymatic activity allele (H) and putative low EPHX1 enzyme
activity, predicted by the combination of Y113H and H139R,
were significantly associated with decreased risk of lung and
UADT cancers, while the putative high EPHX1 enzyme activity
was associated with increased risk of these cancers. Certainly, the
actual EPHX1 enzyme activity should be measured in cancer
case-control population to confirm cancer susceptibility of EPHX1
activity. Moreover, it showed modest difference of the risk of lung
and UADT cancers between cigarette smokers and nonsmokers
both in single SNP analyses and in combined double SNP
analyses. Thus, cigarette-smoking status may influence the
association of EPHX1 enzyme activity and the related cancer risk.
These findings are consistent with the known roles for EPHX1
enzyme in the detoxification and activation of exogenous
carcinogens such as PAHs during tobacco smoking [3]. Lung
and UADT cancers have been well characterized as causally
related to cigarette smoking [104]. Smoking products such as
tobacco-specific nitrosamines (4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone, N’-nitrosonornicotine, etc.), polycyclic aromatic
hydrocarbons (e.g. benzo[a]pyrene) and aromatic amines (e.g. 4-
aminobiphenyl) are strongly toxic to epithelial cells and are
potential carcinogens [105]. The EPHX1 enzyme has been
proposed to transform epoxide intermediates from PAHs into
more reactive carcinogens, such as benzo[a]pyrene-7,8-diol-9,10
epoxide (from benzo[a]pyrene), which is the most mutagenic and
carcinogenic metabolite [4–6]. Thus, high EPHX1 enzymatic
activity could increase the concentrations of carcinogens in the
tissue. Hence, the EPHX1 variants, individually or collectively with
other metabolic enzymes, may lead to cancer susceptibility.
Figure 3. Forest plots describing the association of putative EPHX1 enzyme activities with lung and upper aerodigestive tract
(UADT) cancers. ORs were calculated as (A) putative low activity vs. putative intermediate activity, and (B) putative high activity vs. putative
intermediate activity predicted by genotype combination of polymorphisms Y113H/H139R in lung and UADT cancers. P-values of the ORs are
calculated with the DerSimonian-Laird method using a random effects model and measurements of heterogeneity are based on Cochran’s Q-test and
the inconsistency index I
2.
doi:10.1371/journal.pone.0014749.g003
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polymorphisms Y113H and H139R [7,8]. The present cancer
meta-analysis was motivated by the idea that performing both
single-SNP analysis and two-SNP analysis may provide insights
into the relationship between EPHX1 enzyme activity and cancer
risk. In single SNP analysis, we performed per-allele comparisons
(H vs. Y; R vs. H) and pairwise comparisons (YH vs. YY, HH vs.
YY; HR vs. HH, RR vs. HH) regardless of the inheritance model
(dominant, co-dominant, recessive). Our combination analysis of
two SNPs using the method of Benhamou et al. [9] assumed that
the inheritance model was co-dominant, as the classification of
low, intermediate and high activity was based on the counts of the
high activity allele (H both for Y113H and H139R) of
combination genotypes. We have additionally tested the inheri-
tance model of these two polymorphisms by the Bayesian model-
free approach [106,107]. For lung cancer the results suggested a
co-dominant inheritance model for the polymorphisms Y113H
(l=0.64, 0.22–0.99) and H139R (l=0.62, 0.27–0.99). But in
UADT this method suggested near dominant for Y113H
(l=0.77, 0.34–1.00) and near recessive model for H139R
(l=0.12, 0.08–0.90).
The xenobiotic metabolism of smoking products is carried out
by both Phase I (e.g. cytochrome P450 family, EPHX1) and Phase
II (e.g. glutathione-S-transferases) enzymes since Phase I enzymes
induce the formation of active carcinogens from procarcinogens,
whereas Phase II enzymes conjugate these compounds and make
them suitable for excretion [108]. It is reasonable to think that the
overall carcinogenic effect of tobacco compounds should be
measured as the final result of the combined action of the two
categories of enzymes. Further study is necessary to confirm the
qualitative gene-gene interaction of these xenobiotic metabolism
enzymes as well as their interaction with tobacco smoking dose in
relation to susceptibility of tobacco-related cancers.
The dispersion extent of effect sizes or between-study hetero-
geneity in a meta-analysis determines the difficulty in drawing
overall conclusions to a great extent [109]. Because the dispersion
in observed effects is partly spurious (it includes both real
difference in effects and also random error), before trying to
interpret the variation in effects we need to determine what part of
the observed variation is real. A critical meta-analysis should
appropriately quantify the heterogeneity and thoroughly ascertain
the caused reasons [110] such as using subgroup analysis, sensitive
analysis and meta-regression. In the present study, both meta-
regression and subgroup analysis by ethnicity revealed that
ethnicity is a source of heterogeneity and have a major influence
on the cancer risk of these two EPHX1 polymorphisms. For
instance, the Y113H low enzymatic activity allele (H) showed
significant association with decreased risk of lung and UADT
cancers in Caucasian (OR=0.87, 95%CI=0.81–0.94) but not
significant in Asian (OR=1.02, 95%CI=0.89–1.16) (Table 2).
The H139R high enzymatic activity allele (R) showed a more
significant association with increased risk of cancer in both Asian
(OR=1.52, 95%CI=1.13–2.05) and African (OR=1.26,
95%CI=1.01–1.57) than that in Caucasian (OR=1.06,
95%CI=0.97–1.15) (Table 2). The minor allele frequency of
these polymorphisms in controls showed significant differences
among different populations (Figure S1), which may have an
impact on the statistical association analysis.
Study sample size was found to be the main source of
heterogeneity for putative high vs. intermediate activity (Table
S4) and the results are inconsistency when the studies were divided
into subgroups of large sample size and small sample size (Table 3).
Intuitively, larger samples studies should reach more convincing
results. However, the large studies still exhibited as quite
heterogeneous. Moreover, two large studies [40,41] contributed
mainly the between-study heterogeneity by applying method of
Patsopoulos et al’s sensitive analysis [23]. After omitted the
heterogeneity-caused studies, putative high activity was signifi-
cantly associated with increased risk of lung and UADT cancers
(OR=1.23, 95%CI=1.06–1.42). Thus, putative high EPHX1
enzyme activity was supposed to increase risk lung and UADT
cancers rather than decrease the risk as results from overall large
sample subgroup analysis suggested.
Publication bias is another main limitation of meta-analysis
which may arise from selective publication or selective inclusion of
literatures. Obvious publication bias was detected from the
analysis for R vs. H of H139R in pooled lung and UADT
cancers. Studies of Zienolddiny [12], Ihsan [56], Graziano[44]
and Wu a [37] were found remarkably deviated from other
symmetrically distributed studies in the Begg’s funnel plot (Figure
S2). These four studies were exactly the source of heterogeneity by
using Patsopoulos et al’s sensitive analysis, which suggests that
omitting heterogeneity-caused studies could reach relatively
pertinent conclusions.
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